Project Grant R01HL175560

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $2.8M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02131, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $242,250 to Duke University to conduct research on the relationship between atrial fibrillation, anticoagulation therapy, and retinal stroke. The key objectives are to: 1) construct an instrumental variable using individual prescriber preference for anticoagulation use and determine its association with the risk of retinal stroke,...
The federal Project Grant award of $100,050.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the potential role of cardiometabolic drugs, such as glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2I), as well as the repurposing of metformin and bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $169,222 to the University of Alabama at Birmingham (UAB) to conduct research on ancestry and sex-related pharmacogenomic and metabolomic signatures that influence the response to oral anticoagulant (OAC) medications. The key objectives of this research project are to: 1) Evaluate pharmacogenomic predictors of direct oral...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $813,824 focuses on developing innovative, technology-driven strategies for the detection and personalized monitoring of aortic stenosis (AS), a progressive narrowing of the aortic valve that affects older adults. The award supports a multi-center pragmatic randomized controlled trial (RCT) to evaluate a two-stage screening approach using artificial intelligence (AI) applied to...
This Project Grant award of $1,262,930.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to examine the influence of cerebral small vessel disease (CSVD) on the net clinical benefit of anticoagulation therapy in intracerebral hemorrhage (ICH) survivors with atrial fibrillation (AF). The key products and services to be delivered include:...
This $834,094 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to advance research on post-stroke cognitive impairment and dementia (PSCID). The funding will support a multi-year effort leveraging a national stroke registry and Medicare data to determine the incidence and prevalence of PSCID, identify associated risk factors, and explore potential pharmacological prevention strategies. Key aspects of the research include a patient-centered approach,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $392,037 to New York University School of Medicine to conduct research on improving cardiovascular outcomes for patients undergoing non-cardiac surgery. The key objectives of the project are to: 1) survey potential study sites to assess their capacity for patient enrollment and management of patients with myocardial injury after non-cardiac surgery (MINS);...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $161,000.00 to the University of California, Davis to investigate sex differences in atrial remodeling and arrhythmia risk in aging. The project will run from September 30, 2024 to August 31, 2026 and aims to advance the understanding of how biological sex impacts the development of atrial fibrillation, a common age-related heart condition. The research will leverage UC Davis's expertise in...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop effective, scalable tools and interventions to reduce postoperative mortality, delirium, cognitive decline, and other adverse outcomes in vulnerable elderly surgical patients. The 5-year, $801,268 award to the University of Pittsburgh will fund research to create reliable preoperative risk prediction models and enable proactive multimodal perioperative interventions, including...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) is providing $2,331,210 to the University of Maryland, Baltimore to develop novel analytical methods to better understand and predict post-fracture recovery trajectories in older adults living with Alzheimer's disease and related dementias (ADRD). The key products and services to be delivered include: Novel machine learning-assisted methods to identify unique patient characteristics...

UTILIZATION AND CLINICAL OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN OLDER ADULTS WITH ATRIAL FIBRILLATION AND FRAILTY - PROJECT SUMMARY ONE IN EVERY 3 PERSONS DEVELOPS ATRIAL FIBRILLATION (AF) IN THEIR LIFETIME, AND AF AFFECTS AT LEAST 10% OF ADULTS AGED 65 YEARS. STROKE PROPHYLAXIS WITH ORAL ANTICOAGULANTS (OAC) IS RECOMMENDED, BUT HALF OF OLDER ADULTS WHO ARE ELIGIBLE FOR OAC ARE NOT TREATED BECAUSE OF CONCERNS FOR MAJOR BLEEDING. TREATMENT WITH OAC IS EVEN LESS FREQUENT IN ADULTS WITH FRAILTY, WHO HAVE EXCESS RISK FOR MAJOR BLEEDING BUT ALSO FOR ISCHEMIC STROKE. TO REDUCE AF RISKS IN VULNERABLE POPULATIONS, LEFT ATRIAL APPENDAGE OCCLUSION (LAAO) WAS APPROVED BY CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) AND IS RECOMMENDED BY PRACTICE GUIDELINES TO PROVIDE AF STROKE PREVENTION FOR INDIVIDUALS DEEMED UNSAFE FOR LONG-TERM OAC. HOWEVER, GIVEN ITS SHORT-TERM PROCEDURAL COMPLICATIONS AND LIFE- LONG REQUIREMENT FOR ANTIPLATELET THERAPY, THE OVERALL BENEFIT OF LAAO AMONG ADULTS WITH FRAILTY IS UNKNOWN. IN FACT, BECAUSE LAAO'S EFFICACY AND SAFETY WERE ESTABLISHED AGAINST OAC IN RANDOMIZED CONTROLLED TRIALS (RCT) OF OAC-ELIGIBLE PATIENTS, LAAO'S EFFECTIVENESS AND SAFETY REMAIN UNCERTAIN FOR THE POPULATION MOST LIKELY TO BENEFIT-PATIENTS WITH FRAILTY OR OAC INELIGIBILITY-RESULTING IN A CRITICAL EVIDENCE-PRACTICE GAP. THE LONG-TERM GOAL OF OUR AF OUTCOMES RESEARCH PROGRAM IS TO IMPROVE EVIDENCE-BASED, PATIENT-CENTERED CARE FOR OLDER ADULTS WITH AF. TO THIS END, OUR CURRENT OBJECTIVE IS TO EVALUATE UTILIZATION AND OUTCOMES OF LAAO COMPARED TO THERAPEUTIC ALTERNATIVES IN OLDER ADULTS WITH FRAILTY. WE WILL UTILIZE MULTIPLE REAL-WORLD DATA SOURCES AND APPLY ADVANCED CAUSAL INFERENCE METHODS TO ENHANCE GENERALIZABILITY AND THE VALIDITY OF INFERENCE. IN AIM 1 WE WILL DETERMINE CHARACTERISTICS OF OLDER ADULTS WHO RECEIVED LAAO AND CHARACTERIZE CONCORDANCE OF LAAO USE WITH CMS APPROVED AND GUIDELINE RECOMMENDED INDICATION. IN AIMS 2 AND 3 WE WILL DETERMINE EFFECTIVENESS, SAFETY, AND NET BENEFIT (HOME TIME) OF LAAO COMPARED TO OAC AND NO OAC, RESPECTIVELY. IN ABSENCE OF RCTS, THE PROPOSED RESEARCH WILL BE THE MAIN SOURCE OF EVIDENCE FOR GUIDING RATIONAL USE OF LAAO IN VULNERABLE POPULATIONS.

Posted 6/14/24